Simultaneous blockade of multiple immune system inhibitory checkpoints enhances anti-tumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model

Ping Yu¹, Jason C. Steel¹, Meili Zhang¹,², John C. Morris¹, Thomas A. Waldmann¹.
¹Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. ²Laboratory Animal Science Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, 21702, USA.

(WORD COUNT EXCLUDING REFERENCES = 4,947)

Corresponding author:

Thomas A. Waldmann, M.D.
Building 10, Room 4N115
10 Center Drive,
Bethesda, MD 20892-1374
TEL: (301) 496-6656
FAX: (301) 496-9956
E-mail: tawald@mail.nih.gov

Key words: Antibody, checkpoint blockade, cytotoxic T-lymphocyte antigen-4, interleukin-15, programmed death ligand-1.

Running title: IL-15 and checkpoint blockade enhance anti-tumor immunity.

Abbreviations: CTLa-4, cytotoxic T-lymphocyte antigen-4; ELISA, enzyme-linked immunosorbent assay; IL-10, interleukin-10; mIL-15, murine interleukin-15; IL-15Rα, interleukin-15 receptor-alpha; IFNγ, interferon-gamma; MHC, major histocompatibility complex; MFI, mean fluorescence intensity; PD-1, programmed death-1; PD-L1, programmed death ligand-1.

(140 words)
Translational Relevance: (Word count = 140)

Interleukin-15 has recently entered clinical trials for treatment of cancer. IL-15 stimulates natural killer cells, and CD8+ effector and memory T-cell immunity. However, IL-15 as monotherapy may not be optimal. We found that IL-15 also increased the expression of the PD-1 inhibitory molecule on the surface of CD8+ T-cells and also stimulated the secretion of the immunosuppressive cytokine, IL-10. To maximize the clinical efficacy of IL-15, the removal of immune inhibitory checkpoints may be necessary. In the present study we accomplished this through the simultaneous use of anti-PD-L1 and anti-CTLA-4 antibodies. We show that blockade antibodies combined with IL-15 lead to decreased expression of PD-1, reduced IL-10 secretion, and increased survival of mice with metastatic CT26 colon cancer. The present study supports a clinical trial combining IL-15 immunotherapy with the simultaneous blockade of CTLA-4 and the PD-1 T-cell inhibitory regulators.
Abstract (Word count = 222 Abstract only)

Purpose: Interleukin-15 (IL-15) is a promising cytokine for immunotherapy of cancer due to its ability to stimulate NK-, B- and T-cell immunity. Its effectiveness, however, may be limited by inhibitory checkpoints and pathways that can attenuate immune responses. Finding strategies to abrogate these negative regulators and enhance the efficacy of IL-15 is a critical challenge.

Experimental Design: In a pre-clinical study we evaluated IL-15 combined with antibodies to block the negative immune regulators CTLA-4 and PD-L1 in a metastatic murine CT26 colon carcinoma model.

Results: IL-15 treatment resulted in a significant prolongation of survival in mice with metastatic tumor. Administration of IL-15, however, also increased expression of PD-1 on the surface of CD8^+ T-cells including CD8^+CD44^high memory phenotype T-cells. Moreover, IL-15 also increased the secretion of the immunosuppressive cytokine, IL-10. Combining IL-15 with anti-PD-L1 and anti-CTLA-4 (multiple immune checkpoint blockade) exhibited greater CTL killing and interferon-gamma secretion. Moreover, this combination resulted in a significant reduction in surface expression of PD-1 on CD8^+ T-cells, a decrease in IL-10 secretion and lead to significantly longer survival of tumor-bearing animals compared to mice treated with IL-15 alone, or combined singularly with anti-PD-L1 or anti-CTLA-4.

Conclusions: Combining the immune stimulatory properties of IL-15 with the simultaneous removal of two critical immune system inhibitory checkpoints we demonstrated enhancement of immune responses leading to increased anti-tumor activity.
Introduction

Interleukin-15 (IL-15), a member of the 4-α-helix bundle family of cytokines is required for the generation of natural killer (NK) cells and lasting CD8⁺ memory T-cell responses (1). IL-15 is trans-presented by its receptor, IL-15Rα, expressed on the surface of antigen presenting cells to the IL-2Rβ and common gamma (γc) chains expressed on effector T-, B- and NK cells (2, 3). IL-15 facilitates the survival and differentiation of these cells, their activation, and the maintenance of memory T-cells (4, 5). In preclinical studies, IL-15 has been shown to enhance both humoral and cell-mediated immune responses leading to the inhibition of tumor growth (6-9).

A number of inhibitory receptors have been demonstrated to dampen or terminate immune responses in the setting of chronic viral infections and in tumor-bearing animals. These include programmed death-1 (PD-1, CD274) (10), and its ligands, PD-L1 and PD-L2 (11), and cytotoxic lymphocyte antigen-4 (CTLA-4). PD-1, a member of the CD28/CTLA-4 family of T-cell regulatory receptors that is expressed on the surface of activated B- and T-cells and is involved in the induction of immune tolerance (12). PD-L1 is constitutively expressed at low levels on hematopoietic cells, including resting T-, B-, myeloid and dendritic cells, as well as some non-hematopoietic cells in the lung, heart and other organs (13). PD-L1 is up-regulated during T-cell activation and it has been shown to interact with PD-1 and CD80. The interaction of PD-1 with its ligands results in an inhibitory signal in activated T-cells that promotes apoptosis and anergy. Similarly, the interaction of PD-L1 and CD80 also delivers an inhibitory signal to activated T-cells (14). Chronic stimulation of PD-1 may result in T-cell “exhaustion”
and the attenuation of immune responses (15). Tumors may exploit these checkpoint controls to inhibit anti-tumor immune responses.

CTLA-4 (CD152), a member of the immunoglobulin superfamily is recognized as another important negative-regulator of the immune response(16). CTLA-4 is expressed on the surface of T-cells and exhibits immunosuppressive function, down-regulating T-cell activation in response to engagement of the T-cell receptor. Blockade of the interaction of CTLA-4 with its ligands, CD80 and CD86 using monoclonal antibodies can reverse inhibition of activation and stimulate T-cell proliferation that leads to enhanced anti-tumor immunity in preclinical models and in patients (17, 18). The combined blockade of both the PD-1 and CTLA-4 pathways in conjunction with an anti-tumor vaccine was recently reported (19). The combination of anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies along with a gene-modified tumor cell vaccine increased the numbers of tumor infiltrating T-cells in a mouse B16 melanoma model. This strategy resulted in greater tumor rejection compared to the vaccine without the blockade of the two critical checkpoints.

In the present study, we demonstrated that in addition to its immunostimulatory effect, IL-15 also increased expression of the negative T-cell regulator, PD-1 and enhanced secretion of the immunosuppressive cytokine IL-10. Blockade of multiple negative immune checkpoints by the simultaneous administration of monoclonal antibodies directed against PD-L1 and CTLA-4 reduced expression of PD-1, secretion of IL-10, and enhanced IL-15-mediated immune responses and provided greater therapeutic benefit in a metastatic murine CT26 colon carcinoma model.
Materials and Methods

Mice. Female 6–8 week-old BALB/c mice were obtained from NCI-Frederick and were maintained in the National Cancer Institute (NCI) animal holding facility. Animal use adhered to NIH Laboratory Animal Care Guidelines and was approved by the NCI Animal Care and Use Committee.

Cell lines. The CT26 cell line, a N-nitro-N-methylurethane–induced BALB/c murine colon carcinoma cell line was purchased from American Type Culture Collection (Manassas, VA) and maintained in RPMI 1640 (Invitrogen, Gaithersburg, MD) supplemented with 10% FCS, L-glutamine, sodium pyruvate, streptomycin, and penicillin (Invitrogen).

Animal model and assessment of treatment effect. Groups of 5 or 6 mice were injected with 2 x 10^5 CT26 tumor cells by the tail vein on day 0. Treatment was begun one day later (day 1). The mice each received 5 μg of mIL-15 (PeproTech, Rocky Hill, NJ) intraperitoneally daily, five times a week for three weeks. Along with mIL-15, some groups of animals also received anti-mouse-PD-L1 antibody (clone 9G2, Bio-express, West Lebanon, NH), anti-CTLA-4 antibody (clone UC10-4F10-11, Bio-express), or both anti-mouse-PD-L1 and anti-CTLA-4 antibodies or as a control, an irrelevant isotype IgG (Bio-express). The dose and schedule of these antibodies was 100 μg/injection administered twice a week for two weeks. Control mice received injections of phosphate buffered saline (PBS; Biofluids, Rockville, MD). On day 21, the mice were euthanized by CO₂ inhalation, their lungs harvested and the tumor nodules counted. In brief, the lungs were stained by intratracheal administration of India ink, removed, fixed in Fekete’s solution, and metastatic nodules >1 mm counted under a dissection microscope. In a matched
series of experiments, similar treatment groups were followed daily for survival. Mice were humanely sacrificed using prospective ACUC-approved criteria to generate survival curves.

**In vivo CD8⁺ T-cell depletion.** Groups of mice (N = 10) were injected intravenously with 2 x 10⁵ CT26 cells on day 0 and then received mIL-15 as described above. Groups of animals received 200 μg of either rat-anti-mouse-CD8 (clone 2.43, Bio-express) or an isotype control rat IgG (clone LTF-2, Bio-express) intraperitoneally beginning on days 0 and 1, and then three times a week for three weeks. Animal survival was followed daily.

**Flow cytometry and immunophenotyping.** Expression of MHC class I on CT26 cells was analyzed by staining with FITC-anti-mouse-H-2Kd. Isotype matched IgG was utilized as a control. In order to compare the effects on the immunophenotype of CD8⁺ T-cells of the mIL-15 and antibody combination treatments, surface expression of PD-1 on the CD8⁺ T-cells as well as the CD8⁺CD44<sup>high</sup> cell populations was evaluated using flow cytometry. Spleen cells were stained with APC-conjugated anti-mouse-CD8 (53-6.7), PE-Cy5.5-conjugated anti-mouse-CD44 (IM-7) and PE-conjugated anti-mouse-PD-1 (RPM-4) or with an isotype control, and incubated for 30 min on ice. Fc receptor binding was minimized by pre-incubation of the cells with rat anti-mouse CD16/CD32. All fluorescent-labeled antibodies were obtained from BD Biosciences (San Jose, CA). Immunofluorescence analysis was performed on a FACSCalibur (BD Biosciences) and analyzed with FlowJo software (Tree Star, Ashland, OR).

**Measurement of IFNγ and IL-10 secretion.** Splenic CD8⁺ T-cells of animals treated with mIL-15 alone or in combination with anti-PD-L1 and/or anti-CTLA-4 were isolated using a magnetic column (Miltenyi Biotec, Auburn, CA). In brief, each spleen was processed into a single cell suspension, incubated with anti-mouse-CD8α microbeads and sorted using a LS
magnetic column according to the manufacturer’s instructions (Miltenyi Biotec). The CD8\(^+\) T-cell fractions were >94% pure as assessed by flow cytometry.

Cytokine secretion by splenic CD8\(^+\) T-cells from tumor-bearing animals was assayed by incubating CD8\(^+\) T-cells (2 \(\times\) 10\(^5\)/well) on anti-mouse CD3 (clone 2C11, BD Biosciences) (10 \(\mu\)g/ml) coated plates with 1 \(\mu\)g/ml soluble anti-mouse CD28 (clone 37.51, BD Biosciences) for 72 hours and then collecting the supernatants. Splenic CD8\(^+\) T-cells co-cultured with the same concentrations of isotype-matched antibodies were set up to control for background. IFN\(\gamma\) and IL-10 were measured by an ELISA (R&D Systems, Minneapolis, MN). The cytokine concentration in the supernatants was interpolated from the linear portion of the ELISA standard curve.

The ability of naïve BALB/c splenic CD8\(^+\) T-cells to respond to mIL-15, anti-PD-L1 and anti-CTLA-4 ex-vivo was also examined. Naïve BALB/c splenic CD8\(^+\) T-cells were incubated with mIL-15 at a concentration of 20 ng/mL alone or in combination with anti-mouse-PD-L1 (10 ng/mL) and/or 10 ng/mL anti-mouse-CTLA-4 or 10ng/ml isotype IgG. Meanwhile, CD8\(^+\) T cells co-cultured with different concentrations of mIL-15 were included. These cells were incubated on anti-mouse-CD3-coated plates (10 \(\mu\)g/mL or 4 \(\mu\)g/mL as indicated) with 1 \(\mu\)g/mL soluble anti-mouse-CD28 for 72 hours and the concentration of IL-10 secretion was determined by ELISA, as described above. Co-culture with media without mIL-15 was used as a control.

**Detection of intracellular IFN\(\gamma\) and cytotoxicity.** Single cell suspensions of spleen cells were prepared from mice sacrificed on day 21 after CT26 tumor challenge and cultured with irradiated (100 Gy) CT26 tumor cells at a ratio of 50:1. Recombinant hIL-2 (Hoffmann-LaRoche Inc, Nutley, NJ) was added to a concentration of 10-15 U/mL. After 4 days, 1 \(\times\) 10\(^6\) effector cells
were cultured with CT26 tumor cells at a ratio of 20:1 for 6 hours. Brefeldin A (10 μg/mL, Sigma, St. Louis, USA) was added to the cultures for the last 5 hours to prevent secretion of the intracellular protein. Cells from each group were first incubated with APC conjugated anti-mouse-CD8 Ab (clone 53-6.7, BD Biosciences) on ice for 30 minutes. The cells were fixed and permeabilized using a Cytotofix/Cytoperm kit as instructed by the manufacturer (BD Bioscience). Briefly, cells were resuspended in a fixing buffer for 20 minutes at room temperature and then washed with permeabilization buffer. Cells were then stained with anti-mouse-IFNγ-PE (clone XMG1.2, BD Bioscience) in permeabilization buffer at 4°C for 30 minutes. Cells were washed in permeabilization buffer, resuspended in FACS buffer, and analyzed on a FACScalibur flow cytometer (Becton Dickinson).

A cytotoxicity assay was performed as follows: effector cells from each of the treatment groups were cultured with 10^4 CT26 target cells/well in triplicate at varying E/T ratios and incubated at 37°C for 4 hours. Cytotoxic activity was measured by LDH release using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI). The percent cytotoxicity was calculated as 100 × ([experimental release] – [effector spontaneous release] – [target spontaneous release])/([target maximum release] – [target spontaneous release]).

Statistical analysis. Kaplan–Meier non-parametric regression analysis was performed to assess the survival time of tumor-bearing animals with significance determined by the log-rank test using JMP statistical software (SAS Institute, Cary, NC). The comparison of cytokine secretion between groups was analyzed by using an unpaired Student’s t test. A value of p < 0.05 was considered significant.
Results

Characterization of tumor cells responding to mIL-15.

In order to examine the potential for CT26 tumors to serve as targets of CD8+ CTL we examined MHC class I expression on these cells. CT26 cells in vitro (Fig. 1A) or ex vivo from lung nodules of tumor-bearing animals (Fig. 1B) demonstrated high levels of MHC class I expression with mean fluorescence intensities (MFI) of 391.2 and 407.4, respectively suggesting that these tumors may be targeted by CD8+ cytolytic T-cells.

To see if IL-15 could induce CD8+ CTL-mediated protection against tumor, mIL-15 was administered beginning one day after intravenous injection of $2 \times 10^5$ CT26 tumor cells and the mice followed for survival (Fig. 1C). Animals treated with mIL-15 demonstrated longer survivals compared to control mice receiving PBS control ($P<0.05$). The median survival of mIL-15 treated mice was 44 days while those treated with PBS survived a median of 19 days. To determine whether CD8+ T-cells played a role in this effect, we used anti-CD8 antibody to deplete CD8+ T-cells. The survival advantage afforded by mIL-15 was largely abrogated by the depletion of CD8+ T-cells indicating that they play a major role in protection from tumor in this model (Fig. 1C). Animals administered IL-15 along with an IgG control exhibited no significant difference in survival when compared to IL-15 alone (data not shown).

IL-15 increased PD-1 expression on CD8+ T-cells in vivo.

As increased PD-1 expression on CD8+ T-cells has been shown to attenuate immune responses (9-11), we examined the effects of mIL-15 on the expression of PD-1 on CD8+ T-cells from tumor-bearing animals. Mice treated with mIL-15 showed increased PD-1 expression on
CD8+ T-cells (Fig. 2A and 2C, compared to PBS group, \( P<0.05 \)) as well as on CD8+CD44\(^{\text{high}}\) cells in the spleen (Fig. 2B and 2D, compared to PBS group, \( P<0.05 \)). When anti-PD-L1 was administered, PD-1 expression decreased compared to that seen with mIL-15 treatment alone. This was seen in both the CD8+ T-cells and the CD8+CD44\(^{\text{high}}\) T-cell population (Fig. 2C and 2D, \( P<0.05 \)). Anti-CTLA-4 when used alone did not reduce PD-1 expression on CD8+ T cells (data not shown), however when anti-CTLA-4 and anti-PD-L1 were combined a further decrease in the expression of PD-1, most notably in the CD8+CD44\(^{\text{high}}\) population was noted (Fig. 2D, \( P<0.05 \)).

**IL-15 modulation of cytokine secretion and the effect of checkpoint blockade.**

On day 14 after tumor inoculation, CD8+ T-cells obtained from the spleens of mice in the different treatment groups were stimulated with anti-mouse-CD3 and anti-mouse-CD28, and IFN\(\gamma\) and IL-10 secretion were measured. CD8+ T-cells isolated from animals treated with mIL-15 demonstrated increased IFN\(\gamma\) secretion compared to the PBS control group (\( P<0.05 \)) (Fig. 3A). The addition of anti-PD-L1, or the combination of anti-PD-L1 and anti-CTLA-4 to treatment with mIL-15 resulted in further increases in IFN\(\gamma\) secretion.

Splenic CD8+ T-cells isolated from animals treated with mIL-15 also secreted higher levels of IL-10 compared to those isolated from PBS treated animals (\( P<0.05 \)) (Fig. 3B). Co-administration of antibodies to PD-L1 and CTLA-4 in the mIL-15 treated mice inhibited the secretion of IL-10 below detectable levels (<16 pg/ml). Anti-CTLA-4 alone had no significant effect on either IFN\(\gamma\) or IL-10 secretion compared to PBS treated control animals (data not shown).
To clarify the relationship between IL-15 and IL-10 secretion, splenic CD8+ T-cells were isolated from naïve mice and stimulated with anti-mouse-CD3 and anti-mouse-CD28 as described. Different concentrations of mIL-15 were provided to the cultures, supernatants were collected and IL-10 was quantitated (Fig. 3C). There was a dose-dependent relationship between IL-10 secretion and the concentration of mIL-15. Moreover, if both anti-PD-L1 and anti-CTLA-4 antibodies were added to the culture system along with mIL-15, they significantly reduced IL-10 secretion by CD8+ T-cells compared to mIL-15 alone (P<0.05, Fig. 3D) No statistical difference was observed between mIL-15 (20ng/ml) alone treated cells and mIL-15 (20ng/ml) combined with isotype IgGs (10ng/ml) treated cells (data not shown).

**IL-15 induced CD8+ T-cell CT26 cell-specific IFNγ secretion and lytic activity.**

Tumor-specific IFNγ secretion was detected by intracellular staining of splenic CD8+ T-cells. There was no obvious IFNγ secretion by PBS treated CD8+ T-cells, but mIL-15 treatment as well as mIL-15 combined with anti-PD-L1 and anti-CTLA-4 treated tumor-bearing animals showed a significantly higher number of IFNγ secreting CD8+ T-cells in the spleen (Fig. 4A) compared to the PBS control group (P<0.01). The ability of CD8+ T-cells isolated from tumor-bearing mice to induce CT-26-specific cell lysis was examined (Fig. 4B). CD8+ T-cells isolated from PBS treated animals did not demonstrate any lytic activity against CT26 cells, whereas CD8+ T-cells isolated from mice treated with mIL-15 alone or in combination with anti-PD-L1 and/or anti-CTLA-4 showed increased CD8+ T-cell lytic activity against CT26 cells in an effector:tumor cell ratio-dependent manner.

**IL-15 reduced the number of tumor lung nodules.**
Treatment with IL-15 significantly reduced the number of tumor nodules in the lungs of mice injected with CT26 cells compared to animals receiving PBS, \( P < 0.05 \) (Fig. 5A). Co-administration of anti-PD-L1 and mIL-15 also lead to a reduction of the number of tumor nodules compared to PBS treatment, \( P < 0.05 \) (Fig. 5A). The combination of mIL-15, anti-PD-L1 and anti-CTLA-4 led to a further decrease in the number of pulmonary metastases relative to that observed in the mIL-15 treated group (\( P < 0.05 \)). Representative lungs are shown in Fig. 5B.

**IL-15 increased the survival of CT26 tumor-bearing animals.**

We next examined if mIL-15 in combination with anti-PD-L1 and anti-CTLA-4 could improve the survival of mice with metastatic CT26 tumors (Fig. 6). Mice treated with PBS survived a median of 21 days (range, 19-23 days). Animals treated with anti-CTLA-4 did not show a survival advantage over animals treated with PBS (\( P = 0.075 \)). In contrast, animals treated with anti-PD-L1 alone did exhibit a survival advantage over those treated with PBS (\( P < 0.05 \)); however, when compared to the mIL-15 treated group, their survival was significantly less (\( P < 0.05 \)). Mice receiving mIL-15 demonstrated a significant prolongation of survival when compared with the PBS treated group (\( P < 0.01 \)). Combining mIL-15 with an irrelevant IgG provided no survival advantage compared to mIL-15 alone (data not shown). Combining mIL-15 and anti-CTLA-4 we found that there was no survival advantage compared to treatment with mIL-15 alone (median survival- 46 vs. 45 days, \( P = 0.399 \)). However, when mIL-15 was combined with anti-PD-L1, there was a significant survival benefit with this addition over mIL-15 alone, (median survival- 59 vs. 45 days, \( P < 0.01 \)). The addition of anti-CTLA-4 to mIL-15 and anti-PD-L1 treatment gave the greatest survival benefit compared to mIL-15 treatment alone.
or treatment with mIL-15 in combination with anti-PD-L1 alone, (median survival- 74 vs. 59 days, $P<0.05$).
Discussion

Many immunotherapeutic strategies directed against cancer focus on enhancing effector cell function in an attempt to increase tumor killing. Despite attempts to augment anti-tumor immunity by a variety of approaches, the enthusiasm for many of these approaches has been diminished by the fact that the generation of measurable increases in anti-tumor effector responses have not often correlated with clinical responses. It is now recognized that at least part of this failure is attributable to the presence of numerous naturally occurring negative regulatory pathways that act to limit immunological responses.

IL-15 is a cytokine that is important in the development and homeostasis of several lymphocyte populations including NK, NK/T and CD8+ T-cells (20-25). In addition, IL-15 can also stimulate proliferation; enhance cytotoxicity and up-regulate production of IFNγ by NK and T-cells (20, 21). In the current study, we showed that IL-15 up-regulated IFNγ secretion by CD8+ T-cells and prolonged the survival of tumor-bearing animals. However, IL-15 as monotherapy also suffers from the potential limitations imposed by up-regulation of negative regulatory checkpoints. In this study, we showed that treatment with IL-15 lead to increased expression of PD-1 on CD8+ T-cells, most notably on CD8+CD44high memory phenotype T-cells. Further, we demonstrated that IL-15 also induced the production of IL-10, a negative regulatory cytokine (26), suggesting that IL-15 may work as a “double-edged sword.” In an attempt to address this issue, we studied the effects of IL-15 combined with the removal of a number of these negative immune regulatory checkpoints.

PD-1 is a surface molecule that is over-expressed on apoptotic cells (27). It moved into the immunologists’ sights as a molecule that is also expressed on ‘exhausted’ T-cells from chronic virus-infected patients and in patients with advanced cancer that contributed to poor T-
cell proliferative capacity and incompetent effector function (28-30). One study demonstrated that the numbers of T-cells expressing PD-1 were increased in patients with high-risk renal cell carcinoma (31). Patients with increased numbers of PD-1+ T-cells were at greater risk of cancer-specific death compared with patients whose T-cells exhibited a low expression of PD-1. In addition, one of the PD-1’s ligands, PD-L1 has also become a focus of interest due to its broad expression and negative-regulatory function. Blockade of the PD-1/PD-L1 negative checkpoint has been demonstrated to restore effector CD8+ T-cell responses in chronic infections such as HIV, hepatitis C and lymphocytic choriomeningitis virus (32-34). In addition, monoclonal antibodies to PD-1 have produced tumor responses in clinical trials in patients with advanced cancer (35). In this study we utilized an anti-PD-L1 antibody to block the PD-1/PD-L1 pathway in a murine metastatic colon cancer model. We found that administration of anti-PD-L1 antibody was able to reduce PD-1 expression on CD8+ T-cells following treatment with IL-15 in vivo. Mice treated with the combination of IL-15 with anti-PD-L1 also had CD8+ T-cells that secreted lesser amounts of the immune inhibitory cytokine, IL-10. Moreover, this combination also enhanced IFNγ secretion and prolonged the survival of tumor-bearing animals.

In order to examine if we could further increase the therapeutic benefit provided by eliminating negative checkpoints, we also inhibited CTLA-4. Antibody-mediated CTLA-4 blockade has been shown to improve the outcome of tumor-bearing animals and patients with advanced malignant melanoma (18, 36). Blockade of CTLA-4 has also been shown to inhibit the secretion of IL-10 (37). The removal of CTLA-4 function, in our system, when used alone, compared to PBS, or in combination with IL-15, compared to IL-15 alone, did not lead to a statistically significant survival advantage. However, when used in combination with PD-L1 inhibition and IL-15, showed a significantly prolonged survival when compared to any of these.
agents used individually or in single combination with IL-15. Both PD-1 and CTLA-4 ligation inhibit Akt activation and block T-cell responses by targeting distinct signaling molecules (38). PD-1 engagement inhibits an upstream proximal step blocking phosphatidylinositol-3-kinase (PI3K) activation. In contrast, signaling by CTLA-4 preserves PI3K activity, instead it functions through its binding to phosphatase PP2A leading to the inhibition of Akt phosphorylation and ultimately the inhibition of T-cell activation (38). By blocking both PD-L1 and CTLA-4 we are able to target two pathways leading to Akt activation, the result being a likely synergistic response allowing effective T-cell activation and ultimately an increased therapeutic effect. A recent study Curran et al, found that the combination of CTLA-4 and PD-1/PD-L1 blockade may also have effects on the tumor microenvironment (19). They showed that this combination resulted in increased tumor infiltrating T-cells with a reduction in the T-regulatory cell populations within the tumor. Whether immune-stimulation through IL-15 in combination CTLA-4 and PD-1/PD-L1 blockade leads to similar changes in tumor infiltrating cells is yet to be determined. While Curran and colleagues also used a whole cell anti-tumor vaccine, their results in terms of increased animal survival were similar to ours highlighting the benefit of multiple immune checkpoints removal.

In the present study, we found that to achieve an effective immune response to a tumor not only is activation of the immune system by IL-15 required but also the simultaneous inhibition of two independent negative immune regulatory checkpoints (CTLA-4 and PD-1/PD-L1) that act to attenuate the immune response. While IL-15 effectively activated the immune system against tumor, it also activated negative regulators such as IL-10 and PD-1, potentially limiting its therapeutic efficacy. By using a strategy that combines IL-15 with the simultaneous
blockade of both CTLA-4 and PD-1 pathways, we reduced the expression of IL-10 and PD-1 allowing a stronger immune response and an increased animal survival.
Disclosure of potential conflicts of Interest

The authors disclosed no potential conflicts of Interest.

Acknowledgement

This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. (word count = 3643)
References


Figure legends

Figure 1: CD8\(^+\) T-cells are involved in the anti-tumor response to CT26 mediated by IL-15. Expression of MHC class I on CT26 cells was analyzed by flow cytometry using FITC-anti-mouse-H-2K\(^d\) (open area). An antibody of the same isotype was used as a negative control (filled area). MHC class I mean fluorescence intensity (MFI) of CT26 cells either \(A\); *in vitro* or \(B\); obtained *ex vivo* from lung nodules of tumor-bearing animals treated with PBS is shown. \(C\); Survival of CT26 tumor-bearing mice treated with mIL-15 with and without CD8\(^+\) T-cells depletion is shown. One day after tumor inoculation, mice received 5 µg/day of mIL-15 injected five times a week for three weeks (mIL-15, diamonds). One group of mice were depleted of CD8\(^+\) T-cells (mIL-15 + anti-CD8, squares) using anti-mouse-CD8 antibody administered on days 0 and 1, and then three time a week for three weeks. PBS treated animals served as controls (PBS, dots). The data represent three independent experiments.

Figure 2: Negative immune checkpoint blockade combined with mIL-15 down-regulated surface PD-1 expression on CD8\(^+\) T-cells and CD8\(^+\)CD44\(^{high}\) T-cells that had been mediated by mIL-15. Flow cytometry was used to analyze the PD-1 expression on splenic CD8\(^+\) T-cells as well as on the CD8\(^+\)CD44\(^{high}\) population from the CT26-bearing mice following treatment with PBS, mIL-15, mIL-15 and anti-PD-L1, or mIL-15, anti-PD-L1 and anti-CTLA-4 on day 10 after CT26 tumor inoculation. Surface expression of PD-1 on CD8\(^+\) T-cells was detected using APC-anti-CD8 and PE-anti-PD-1 (open area, Fig. 2A). The CD8\(^+\)CD44\(^{high}\) population was stained with APC-anti-CD8 and PE-Cy5.5-anti-CD44 antibodies (open area, Fig. 2B). An
isotype matched IgG was used as a negative control (filled area). All the samples were analyzed on gated CD8$^+$ T-cells or CD8$^+$CD44$^{\text{high}}$ cells as indicated. MFI is shown. The figure is representative of two independent experiments wherein each group contained three to five animals. Statistical analysis was performed based on PD-1 expression on CD8$^+$ T cells (Fig. 2C) and CD8$^+$CD44$^{\text{high}}$ population (Fig. 2D). * $P<0.05$ and ** $P<0.01$.

Figure 3: The combination of anti-PD-L1 and anti-CTLA-4 antibodies that block negative checkpoints enhanced mIL-15 induced IFN$\gamma$ secretion as well as down-regulated IL-10 secretion by CD8$^+$ T-cells. A and B; Splenic CD8$^+$ T-cells obtained ex vivo from CT26 tumor-bearing mice treated with PBS, mIL-15, mIL-15 and anti-PD-L1, or mIL-15 combined with anti-PD-L1 and anti-CTLA-4 were stimulated with 10 $\mu$g/ml plate-bound anti-CD3 plus 1 $\mu$g/mL of a soluble anti-CD28 antibody and the supernatants were collected after 72 hours. IFN$\gamma$ and IL-10 secretion was quantitated by ELISA. Cells were co-cultured with the same concentration of isotype-matched antibodies as a background control; *$P<0.05$; C, Naïve splenic CD8$^+$ T-cells were stimulated with anti-CD3 (10 $\mu$g/mL, black dots; 4 $\mu$g/mL, grey diamonds) plus 1 $\mu$g/mL of a soluble anti-CD28 antibody in the presence of different amounts of mIL-15 as indicated. IL-10 secretion was quantitated by ELISA. Cells cultured with the same concentration of an isotype control antibody were set up as controls. D, anti-PD-L1 and anti-CTLA-4 (10 ng/mL) were added with 20 ng/mL mIL-15 present in wells at the same stimulation conditions as above (black bars). IL-10 secretion in the supernatants was quantitated by ELISA. Media alone with no mIL-15 was set up as a control, *$P<0.05$. ND: non-detectable ($>16$ pg/ml). The data is representative of three independent experiments.
Figure 4: mIL-15 induced tumor-specific IFNγ secretion and lytic activity. On day 21, CT26-bearing mouse splenocytes were harvested and incubated with irradiated CT26 cells at a ratio of 50:1. Cultures were incubated for 4 days. A, 1 × 10^6 effector cells were cultured with CT26-tumor cells at a ratio of 20:1 for 6 h. Brefeldin A (10 μg/mL) was added to the cultures for the last 5 h. Cells from each group were first stained with APC conjugated anti-CD8, then intracellularly stained with PE-anti-IFNγ. Five hundred thousand events were collected for each sample by a flow cytometer. B; tumor-specific CD8+ T-cell target cell killing activities were detected by a non-radioactive cytotoxicity assay. PBS (open triangles), mIL-15 (open squares), mIL-15 + anti-PD-L1 (filled triangles) and mIL-15 + anti-PD-L1 + anti-CTLA4 (filled diamonds) groups are shown in panel B. The figures are representative of three independent experiments.

Figure 5: IL-15 treatment reduced the number of tumor nodules in the lungs. A; On day 21, pulmonary metastases were counted; each group included 3 to 5 mice, *P<0.05. The data represents three independent experiments. B; Representative lung samples showing pulmonary metastases at day 21.

Figure 6: IL-15 treatment with blockade of multiple inhibitory checkpoints prolonged the survival of CT26 tumor-bearing animals. Kaplan-Meier survival by treatment illustrating tumor bearing animal survival after the different treatments. PBS control (open diamonds), anti-CTLA-4 (open squares), mIL-15 and anti-CTLA-4 (grey squares), mIL-15 (black triangles), anti-PD-L1 (black diamond), mIL-15 and anti-PD-L1 (grey diamonds) and mIL-15 combined with anti-PD-L1 and anti-CTLA-4 (grey circles). The data represent three independent experiments.
Figure 1.

A. In vitro

B. Ex vivo

FITC- rat IgG

FITC-Anti-H-2K^d

C. mIL-15

mIL-15+anti-CD8

PBS

Days post-tumor inoculation

% survival
Figure 2.

A. Flow cytometry histograms showing CD8+ cells. The histograms compare PBS, mIL-15, mIL-15+anti-PD-L1, and mIL-15+anti-CTLA4 treatments.

B. Flow cytometry dot plots for CD8 and CD8+CD44high cells. The dot plots show the distribution of PE-rat IgG and PE-Anti-PD1.

C. Bar graphs showing the percent of PD-1+/CD8+ cells in PBS, mIL-15, mIL-15+anti-PD-L1, and mIL-15+anti-CTLA-4 treatment groups. *p < 0.05, **p < 0.01.

D. Bar graphs showing the percent of PD-1+/CD8+CD44high cells in PBS, mIL-15, mIL-15+anti-PD-L1, and mIL-15+anti-CTLA-4 treatment groups. *p < 0.05, **p < 0.01.
Figure 3.

(A) Bar graph showing IFN-γ (pg/ml) levels with different treatments.

(B) Bar graph showing IL-10 (pg/ml) levels with different treatments.

(C) Line graph showing IL-10 (pg/ml) levels with varying concentrations of Murine IL-15.

(D) Bar graph showing IL-10 (pg/ml) levels with different treatments.

Legend:
- PBS
- mIL-15
- mIL-15 + anti-PD-L1
- mIL-15 + anti-PD-L1 + anti-CTLA-4

**Notes:**
- ND: Not detected
- *p < 0.05 compared to control
Figure 4.

**A**

- PBS
- mIL-15
- mIL-15 + anti-PDL1
- mIL-15 + anti-PDL1 + anti-CTLA4

**B**

- PBS
- mIL-15
- mIL-15 + anti-PDL1
- mIL-15 + anti-PDL1 + anti-CTLA4

% Lysis vs. E/T ratio (6.25/1 to 50/1)
Figure 5.

A

![Graph showing lung tumor nodules/mouse for different treatments.](image)

- PBS
- miL-15
- miL-15 + anti-PDL1
- miL-15 + anti-PDL1 + anti-CTLA4

B

![Images of lung tissues under different conditions.](image)

- PBS
- miL-15
- miL-15 + anti-PDL1
- miL-15 + anti-PDL1 + anti-CTLA4
Figure 6.

% survival

Days post tumor inoculation

PBS

Anti-CTLA4

mIL-15+anti-CTLA4

Anti-PDL1

mIL-15+anti-PDL1

mIL-15+anti-PDL1+anti-CTLA4

0 20 40 60 80 100

0 20 40 60 80 100

0 20 40 60 80 100
Simultaneous blockade of multiple immune inhibitory checkpoints enhance anti-tumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model

Ping Yu, Jason C Steel, Meli Zhang, et al.

Clin Cancer Res  Published OnlineFirst October 5, 2010.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-1966

Supplementary Material  Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2010/12/14/1078-0432.CCR-10-1966.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2010/10/05/1078-0432.CCR-10-1966. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.